Advanced Biologics and Smart Delivery Systems for Cardiovascular Diseases: A Comprehensive Review

Authors

  • Paras Ghasura A-One Pharmacy College, Ahmedabad, Gujarat, India Author
  • Bhavika Murlidhar Sajnani A-One Pharmacy College, Ahmedabad, Gujarat, India Author
  • Mohammad Azhar Tanveer Rajiv Memorial Education Society’s College of Pharmacy, Gulbarga, Karnataka, India Author
  • Barath Raj R C L Baid Metha College of Pharmacy, Tamil Nadu, India Author
  • Dr Abhishek Sharma Hakeem Abdul Hameed Centenary Hospital (HAHC Hospital), India Author

DOI:

https://doi.org/10.32628/IJSRST251268

Keywords:

Cardiovascular diseases, biologics, nano medicine, drug delivery systems, PCSK9 inhibitors, targeted therapy

Abstract

Background: Cardiovascular diseases (CVDs) remain the leading global cause of mortality, accounting for 20.5 million deaths annually. Traditional pharmacotherapies face limitations including poor bioavailability and systemic toxicity. Objective: To review the integration of advanced biological therapeutics with innovative drug delivery platforms for cardiovascular applications. Methods: Systematic analysis of 127 peer-reviewed articles from PubMed, Scopus, and Web of Science databases (2020-2025), focusing on FDA-approved biologics and emerging delivery technologies. Results: PCSK9 inhibitors demonstrate 50-60% LDL cholesterol reduction with significant cardiovascular event reduction. Advanced delivery systems including nanoparticles, stimuli-responsive carriers, and extracellular vesicles enhance therapeutic precision while minimizing adverse effects. Clinical successes include inclisiran achieving sustained efficacy with biannual dosing. Conclusion: The integration of biologics with smart delivery systems represents a paradigm shift toward personalized cardiovascular medicine with significant potential to improve patient outcomes.

📊 Article Downloads

References

Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics-2024 Update. Circulation. 2024;149(8):e347-e913.

Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals. Nat Rev Drug Discov. 2014;13(9):655-672. DOI: https://doi.org/10.1038/nrd4363

Paunovska K, Loughrey D, Dahlman JE. Drug delivery systems for RNA therapeutics. Nat Rev Genet. 2022;23(5):265-280. DOI: https://doi.org/10.1038/s41576-021-00439-4

Mitchell MJ, Billingsley MM, Haley RM, et al. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101-124. DOI: https://doi.org/10.1038/s41573-020-0090-8

Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722. DOI: https://doi.org/10.1056/NEJMoa1615664

Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097-2107. DOI: https://doi.org/10.1056/NEJMoa1801174

Koren MJ, Lundqvist P, Bolognese M, et al. Anti-PCSK9 monotherapy for hypercholesterolemia. J Am Coll Cardiol. 2014;63(23):2531-2540. DOI: https://doi.org/10.1016/j.jacc.2014.03.018

Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-1131. DOI: https://doi.org/10.1056/NEJMoa1707914

Ray KK, Wright RS, Kallend D, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020;382(16):1507-1519. DOI: https://doi.org/10.1056/NEJMoa1912387

Zangi L, Lui KO, von Gise A, et al. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat Biotechnol. 2013;31(10):898-907. DOI: https://doi.org/10.1038/nbt.2682

Gaudet D, Methot J, Dery S, et al. Efficacy and long-term safety of alipogene tiparvovec in patients with lipoprotein lipase deficiency. Gene Ther. 2019;26(6):256-265.

Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078-1094. DOI: https://doi.org/10.1038/s41578-021-00358-0

Danhier F, Ansorena E, Silva JM, et al. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161(2):505-522. DOI: https://doi.org/10.1016/j.jconrel.2012.01.043

Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12(11):991-1003. DOI: https://doi.org/10.1038/nmat3776

Zhang Y, Yu J, Bomba HN, et al. Mechanical force-triggered drug delivery. Chem Rev. 2016;116(19):12536-12563. DOI: https://doi.org/10.1021/acs.chemrev.6b00369

Chen H, Zhang W, Zhu G, et al. Rethinking cancer nanotheranostics. Nat Rev Mater. 2017;2(7):17024. DOI: https://doi.org/10.1038/natrevmats.2017.24

Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977. DOI: https://doi.org/10.1126/science.aau6977

Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics. J Control Release. 2000;65(1-2):271-284. DOI: https://doi.org/10.1016/S0168-3659(99)00248-5

Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261-1268. DOI: https://doi.org/10.1038/nbt.1504

Li J, Mooney DJ. Designing hydrogels for controlled drug delivery. Nat Rev Mater. 2016;1(12):16071. DOI: https://doi.org/10.1038/natrevmats.2016.71

Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2017;376(14):1321-1331. DOI: https://doi.org/10.1056/NEJMoa1700456

Leqvio® (Inclisiran) Prescribing Information. Novartis. 2021.

Repatha® (Evolocumab) Prescribing Information. Amgen. 2015.

Barenholz Y. Doxil®--the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117-134. DOI: https://doi.org/10.1016/j.jconrel.2012.03.020

Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382(3):244-255. DOI: https://doi.org/10.1056/NEJMoa1905239

FDA Breakthrough Therapy Designation Database. 2024. Available at: https://www.fda.gov/drugs/nda-and-bla-approvals/breakthrough-therapy-approvals

Zhang Y, Chan HF, Leong KW. Advanced materials and processing for drug delivery: the past and the future. Adv Drug Deliv Rev. 2013;65(1):104-120. DOI: https://doi.org/10.1016/j.addr.2012.10.003

DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20-33. DOI: https://doi.org/10.1016/j.jhealeco.2016.01.012

Chen R, Liu X, Jin S, et al. Machine learning for drug-target interaction prediction. Molecules. 2018;23(9):2208. DOI: https://doi.org/10.3390/molecules23092208

Seeman NC. DNA nanotechnology. Nat Rev Mater. 2018;3(1):17068. DOI: https://doi.org/10.1038/natrevmats.2017.68

Global Cardiovascular Drug Delivery Market Report 2024. Research and Markets. 2024.

Downloads

Published

11-07-2025

Issue

Vol. 12 No. 4 (2025): July-August

Section

Research Articles

License

Copyright (c) 2025 International Journal of Scientific Research in Science and Technology

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

https://creativecommons.org/licenses/by/4.0